GleamWall
中文EN

EXEL EXELIXIS, INC.

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 939767 · Fiscal year ends 01/01

Financial factors as of 2026-10-02 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY9.1%
TTM net income YoY30.6%
TTM EPS YoY40.3%
Revenue 3-yr CAGR12.1%
Net income 3-yr CAGR112.6%

Margins

Gross margin96.3%
Operating margin40.2%
Net margin35.5%
FCF margin46.5%
EBITDA margin41.3%

Returns

ROE44.3%
ROA33.2%
ROIC (approx.)47.8%
Asset turnover0.94x

Leverage & solvency

Liabilities / assets27.0%
Debt / equity0.00x
Current ratio3.21x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.33x
Accruals ratio-10.8%
Payout ratio—
Capex / revenue0.5%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252026-01-02FY20242025-01-03
Income statement
Revenue$2.32B$2.17B
Cost of revenue$83.70M$76.22M
Gross profit$2.24B$2.09B
R&D expense$825.00M$910.41M
SG&A expense$518.73M$492.13M
Operating income$872.19M$604.62M
Income tax$158.64M$160.37M
Net income$782.57M$521.27M
EBITDA$901.25M$633.42M
EPS (basic)2.881.80
EPS (diluted)2.781.76
Weighted avg. shares (diluted)281.86M296.13M
Balance sheet
Cash & equivalents$482.49M$217.37M
Short-term investments$576.60M$893.90M
Receivables$286.92M$265.44M
Inventory$21.69M$22.39M
Current assets$1.44B$1.47B
PP&E, net$98.96M$119.39M
Goodwill$63.68M$63.68M
Total assets$2.84B$2.95B
Current liabilities$405.64M$403.77M
Total liabilities$683.10M$703.49M
Shareholders' equity$2.16B$2.24B
Shares outstanding262.48M281.73M
Cash flow statement
Operating cash flow$884.27M$699.97M
Capital expenditure$8.43M$28.43M
Free cash flow$875.84M$671.54M
Investing cash flow$350.44M-$116.78M
Financing cash flow-$969.59M-$628.81M
Depreciation & amortization$29.05M$28.80M
Stock-based compensation$112.98M$93.84M
Share buybacks$947.51M$652.03M

Free plan shows the latest 2 periods; Pro shows all 19 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.